Skip to main content

STERIS Value Stock - Dividend - Research Selection

Steris

ISIN: IE00BFY8C754 , WKN: A2PGLV

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Profitable Stock for Long-Term Investors and 2 We Brush Off

2026-04-25
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

STERIS' Q4 2026 Earnings: What to Expect

2026-04-22
STERIS will release its fourth-quarter earnings soon, and analysts anticipate a single-digit bottom-line growth.

STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026

2026-04-21
DUBLIN, IRELAND, April 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 fourth quarter and full year results at 9:00 a.m. ET on May 12, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial re

Surgical Equipment & Consumables - Diversified Stocks Q4 Earnings: STERIS (NYSE:STE) Firing on All Cylinders

2026-04-20
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at STERIS (NYSE:STE) and its peers.

Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?

2026-04-16
Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

STERIS PLC (NYSE:STE) Passes the "Caviar Cruise" Quality Investing Screen

2026-04-13
STERIS PLC exemplifies quality investing with strong revenue growth, high capital returns, and a robust balance sheet, making it a standout for long-term portfolios.

A Look At STERIS (STE) Valuation After Recent Share Price Weakness And Long Term Gains

2026-04-10
Why STERIS Stock Is on Investors’ Radar Today STERIS (STE) is back in focus after recent share price moves, with the stock showing mixed short term results that include a 1 day decline, a small 7 day gain, and a modest month return. See our latest analysis for STERIS. At a share price of US$223.75, STERIS has seen short term share price weakness, including a 90 day share price return of a 12.88% decline. However, longer term total shareholder returns, such as 4.08% over one year and 18.07%...

Is This the Right Time to Hold STERIS Stock in Your Portfolio?

2026-04-08
STE rides on strong Healthcare and AST growth, but FX swings, tariffs, and rising costs cloud the outlook for investors.

1 S&P 500 Stock Worth Your Attention and 2 We Find Risky

2026-04-06
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

STARR PEAK PLANS FOLLOW UP DRILL PROGRAM FOR HIGH POTENTIAL BHEM COPPER TARGET

2026-04-01
Starr Peak Mining Ltd. ("Starr Peak" or the "Company") (TSXV: STE) (OTCQX: STRPF) is pleased to announce plans to drill the deep target at Normetmar resulting from the 2022 BHEM1 investigation. This target is positioned underneath Normetmar mineralization upper two zones, approximately 900 meters to the West of the past-producing Normétal Mine (10.1Mt @ 2.15% Cu, 5.12% Zn, 0.55 g/t Au, 45.25 /t Ag), located in the Abitibi Greenstone Belt of Québec.